BioSpace News Archive

Aravive Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced that it received a $6 million development milestone payment from its licensee, 3D Medicines Inc.

DermTech, Inc., a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced its presentation at the Biomarkers & Precision Medicine USA Congress, held from Oct. 3-4 in San Diego.

Novanta Inc. (Nasdaq: NOVT) (the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, will release its third quarter 2022 results on Tuesday, November 8, 2022.

Mirum Pharmaceuticals, Inc. announced that on October 10, 2022, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 52,650 shares of common stock and 26,400 restricted stock units to nine new employees under Mirum’s 2020 Inducement Plan.

The Biotechnology Innovation Organization – the world’s largest science and public advocacy organization, representing 1,000 members — announced that Rachel King, co-founder and former CEO of GlycoMimetics, Inc., has agreed to serve as interim President and CEO.

HUTCHMED Limited announces that it has initiated a Phase II/III trial of sovleplenib in adult patients with warm antibody autoimmune hemolytic anemia in China.

G1 Therapeutics, Inc., a commercial-stage oncology company, announced that the last patient has been randomized in PRESERVE 2, G1’s Phase 3 clinical trial of trilaciclib in patients with metastatic triple negative breast cancer receiving chemotherapy.

Acorda Therapeutics, Inc. announced that the company has withdrawn Proposal One, a request to increase the number of authorized shares of Acorda stock, from the ballot for the Special Meeting of Stockholders scheduled for November 4, 2022.

Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Tuesday, November 1, 2022 , at 8:00 a.m. CDT to review first quarter 2023 financial results.

BELLUS Health Inc. today announced that an abstract reviewing clinical data from the Phase 2b SOOTHE trial will be presented at the upcoming CHEST Annual Meeting, being held in Nashville, Tennessee from October 16-19, 2022.